Design Therapeutics, Inc. (NASDAQ:DSGN) Shares Sold by Two Sigma Investments LP

Two Sigma Investments LP decreased its stake in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 33.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 203,931 shares of the company's stock after selling 100,313 shares during the quarter. Two Sigma Investments LP owned approximately 0.36% of Design Therapeutics worth $1,258,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of DSGN. Point72 Asset Management L.P. boosted its position in Design Therapeutics by 16.0% during the fourth quarter. Point72 Asset Management L.P. now owns 1,856,750 shares of the company's stock worth $11,456,000 after purchasing an additional 256,010 shares in the last quarter. ProShare Advisors LLC acquired a new position in shares of Design Therapeutics during the fourth quarter valued at approximately $71,000. MPM Bioimpact LLC acquired a new position in shares of Design Therapeutics during the fourth quarter valued at approximately $3,452,000. Driehaus Capital Management LLC acquired a new position in shares of Design Therapeutics during the fourth quarter valued at approximately $4,788,000. Finally, BNP Paribas Financial Markets acquired a new position in shares of Design Therapeutics during the fourth quarter valued at approximately $249,000. Hedge funds and other institutional investors own 56.64% of the company's stock.

Design Therapeutics Stock Up 0.2%

Shares of Design Therapeutics stock traded up $0.01 during mid-day trading on Friday, reaching $4.01. 119,154 shares of the stock traded hands, compared to its average volume of 184,957. The business has a 50-day moving average of $3.69 and a 200 day moving average of $4.67. Design Therapeutics, Inc. has a fifty-two week low of $2.60 and a fifty-two week high of $7.77. The stock has a market capitalization of $227.64 million, a PE ratio of -4.72 and a beta of 1.62.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.03). On average, equities research analysts expect that Design Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Design Therapeutics Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.